Search - tctmd.com

Displaying 101 - 120 of 671

Sort: Relevancy | Date

Presentation OPCI 2019

Optimal Duration of Antiplatelet Therapy – Does IV Imaging Make A Difference?

Presenter: Roxana Mehran

March 09, 2019

Presentation OPCI 2019

High Definition IVUS as a tool to optimize PCI

Presenter: Akiko Maehara

March 09, 2019

Presentation OPCI 2019

Basics of Coronary Physiology: FFR-Guided PCI in Stable CAD

Presenter: William F. Fearon

March 09, 2019

Presentation JIM 2019

Log-linear association per unit change in LDL-C and the risk of CV disease-a statin tale

Presenter: Bernardo Cortese

February 15, 2019

Presentation JIM 2019

GP IIb/IIIa inhibitors are still the best option

Presenter: Alberto Menozzi

February 15, 2019

Presentation JIM 2019

Consider Low Dose RIVAROXABAN + SAPT

Presenter: Roxana Mehran

February 15, 2019

Presentation JIM 2019

Clinical case: Management of long-term antithrombotic therapy

Presenter: Giuseppe Tarantini

February 15, 2019

Presentation JIM 2019

Cangrelor is ready for the prime time

Presenter: Giuseppe Musumeci

February 15, 2019

Presentation ISC 2019

Treatment of Factor Xa Inhibitor-Associated Bleeding with Andexanet Alfa: Full Results of ANNEXA-4

Presenter: Stuart J. Connolly

February 08, 2019

Presentation

Predictors and Outcomes of Staged vs One-Time Revascularization in Multivessel CAD

November 20, 2018

Presentation Controversies and Advances 2018

Updateon PCS K-9 Inhibition

Presenter: P.K. Shah

November 15, 2018

Presentation AHA 2018

Ticagrelor vs Aspirin in Patients undergoing Coronary-Artery Bypass Grafting

Presenter: Heribert Schunkert

November 14, 2018

Presentation

Newer-Generation Ultrathin-Strut DES vs Older Second-Generation Thicker-Strut DES for CAD

July 11, 2018

Presentation

Trends in P2Y12 Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After PCI, 2008-2016

May 21, 2018

Presentation Intravascular Coronary Imaging and Physiology 2018

Combined analysis of DEFINE-FLAIR and iFR Swedeheart: Safety of PCI deferral in stable CAD and ACS

Presenter: Allen Jeremias

May 06, 2018

Presentation Intravascular Coronary Imaging and Physiology 2018

PCI should not be first line therapy for patients with stable CAD – Lessons learned from ORBITA

Presenter: Rasha Al-Lamee

May 05, 2018

Presentation

Preangioplasty iFR Pullback Predicts Hemodynamic Outcome in CAD: iFR GRADIENT Registry

April 17, 2018

Presentation Fellows 2018

ACS Pharmacology for the Interventionalist

Presenter: Duane S. Pinto, Gregg W. Stone

April 13, 2018

Presentation CIT 2018

Optimal Pharmacology and PCI Strategy in STEMI & Multivessel Disease

Presenter: Ran Kornowski

March 23, 2018

Presentation ACC 2018

6-Month versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE)

Presenter: Hyeon-Cheol Gwon

March 12, 2018

Advertisement

Optimal Duration of Antiplatelet Therapy – Does IV Imaging Make A Difference?

High Definition IVUS as a tool to optimize PCI

Basics of Coronary Physiology: FFR-Guided PCI in Stable CAD

Log-linear association per unit change in LDL-C and the risk of CV disease-a statin tale

GP IIb/IIIa inhibitors are still the best option

Consider Low Dose RIVAROXABAN + SAPT

Clinical case: Management of long-term antithrombotic therapy

Cangrelor is ready for the prime time

Treatment of Factor Xa Inhibitor-Associated Bleeding with Andexanet Alfa: Full Results of ANNEXA-4

Predictors and Outcomes of Staged vs One-Time Revascularization in Multivessel CAD

Updateon PCS K-9 Inhibition

Ticagrelor vs Aspirin in Patients undergoing Coronary-Artery Bypass Grafting

Newer-Generation Ultrathin-Strut DES vs Older Second-Generation Thicker-Strut DES for CAD

Trends in P2Y12 Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After PCI, 2008-2016

Combined analysis of DEFINE-FLAIR and iFR Swedeheart: Safety of PCI deferral in stable CAD and ACS

PCI should not be first line therapy for patients with stable CAD – Lessons learned from ORBITA

Preangioplasty iFR Pullback Predicts Hemodynamic Outcome in CAD: iFR GRADIENT Registry

ACS Pharmacology for the Interventionalist

Optimal Pharmacology and PCI Strategy in STEMI & Multivessel Disease

6-Month versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content